Foundayo
Foundayo (orforglipron) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist tablet taken once daily with a reduced-calorie diet and increased physical activity to help adults with obesity or overweight plus weight-related comorbidities lose excess body weight and maintain weight loss.
Brief glance
Foundayo is a branded drug product manufactured by Eli Lilly. Its active substance is Orforglipron. The linked substance is commonly grouped under “Weight Loss” as a primary outcome. FDA status: Approved. First FDA approval on record: Apr 2026. It is not currently flagged on our shortage list.
Overview
Foundayo (orforglipron) is an oral, once-daily glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition, used in combination with a reduced-calorie diet and increased physical activity. The medication works by mimicking the natural GLP-1 hormone to regulate appetite, slow gastric emptying, and reduce hunger signals, with clinical trials demonstrating an average of 12.4% weight loss at the highest dose compared to placebo. As a non-peptide small molecule, Foundayo can be taken without food or timing restrictions, distinguishing it from injectable GLP-1 medications and other peptide-based oral formulations.
Foundayo (orforglipron) is a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management. It is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight loss long-term in adults with obesity or overweight accompanied by at least one weight-related comorbidity. As a non-peptide GLP-1 agonist, Foundayo mimics the GLP-1 hormone to slow gastric emptying, reduce appetite, and regulate blood sugar by targeting GLP-1 receptors. Clinical trials demonstrated statistically significant weight reductions of up to 11-14% over 72 weeks compared to placebo. Treatment typically starts at 0.8 mg, with titration to higher doses up to 17.2 mg based on response and tolerability.
Benefits
Foundayo (orforglipron) is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, used alongside reduced-calorie diet and increased physical activity.1,2,3 Clinical trials demonstrate average weight loss of 10-15% of body weight, or about 25 pounds (11.1%), through mechanisms including appetite suppression, delayed gastric emptying, increased insulin secretion, and reduced glucagon production.3,4,5,6 Additional benefits include improvements in cardiometabolic markers such as reductions in HbA1c (1.5-2.0%), waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol.4,5,7 As an oral non-peptide GLP-1 receptor agonist, it provides once-daily dosing without food or water restrictions, enhancing adherence compared to injectables.3,4,5
Side effects
The most common side effects of Foundayo (orforglipron) are gastrointestinal issues including nausea (26-35%), constipation (20-27%), diarrhea (21-25%), vomiting (13-24%), indigestion (12-16%), abdominal pain (13-14%), bloating, gas, burping, and heartburn, along with headache (8-9%), fatigue, decreased appetite, and hair loss, which are typically mild and may improve over time with gradual dose escalation.1,2,8,9,10 Serious adverse effects can include severe stomach problems, pancreatitis (with severe upper abdominal pain radiating to the back), gallbladder issues (upper stomach pain, fever, jaundice, clay-colored stools), low blood sugar (hypoglycemia, especially with insulin or sulfonylureas, presenting as shakiness, sweating, confusion), serious allergic reactions (swelling of face/lips/tongue/throat, breathing difficulty, rash), possible thyroid tumors (neck lump, hoarseness, trouble swallowing), and increased risk of pulmonary aspiration during surgery or sedation due to delayed gastric emptying.1,2,9,10,11,12 Patients with type 2 diabetes should monitor for vision changes, and all users must inform healthcare providers before procedures requiring anesthesia.1,10 Safety considerations include starting at a low dose to minimize GI effects, staying hydrated, eating smaller meals, and promptly reporting persistent or severe symptoms.8,9
Mechanisms of action
Foundayo (orforglipron) is a GLP-1 receptor agonist that binds to and activates the human GLP-1 receptor.1,13,14,15 GLP-1 receptors are located in brain regions that regulate appetite and caloric intake, and activation by Foundayo reduces appetite and food intake.1,13,15 It also delays gastric emptying, with the greatest effect after the first dose that diminishes over time.13 In animal studies, orforglipron distributed to and activated neurons in these brain regions, supporting its role in appetite suppression.13,15 These actions contribute to decreased body weight, primarily through fat mass loss.13